Skip to main content
Skip to navigation

Studying Drug Resistance in HIV -Subtype B & C


 
There are more than 30 million individuals throughout the world who are infected by various subtypes of HIV. Numerous therapeutic and clinical trials have been developed for patients with HIV subtype B because it is the most prevalent in the United States. However, subtype B accounts for only 12% of infections worldwide. The goal of this research project is to expand upon understanding and treatment of subtype B and optimize treatments for the more than 15 million patients infected with subtype C.

For more information, contact Stefan Sarafianos at sarafianoss@missouri.edu or (573) 882-4338.  

Related Initiative(s):
One Health/One Medicine

Project tagged as: , ,